concurrent chemoradiotherpay
Showing 51 - 75 of 2,089
Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course
Recruiting
- Locally Advanced Rectal Cancer
- Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
- Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Apr 25, 2023
Head Neck Cancer Trial in Billerica, Darmstadt (Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT))
Not yet recruiting
- Head and Neck Cancer
- Xevinapant
- +2 more
-
Billerica, Massachusetts
- +1 more
Sep 20, 2023
Oral Cavity Squamous Cell Carcinoma Trial in Yichang (Sintilimab, Radiotherapy)
Recruiting
- Oral Cavity Squamous Cell Carcinoma
- Sintilimab
- Radiotherapy
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Feb 18, 2023
Fibromyalgia Trial in Talavera De La Reina (Real UHCDS a-tDCS, Therapeutic exercise, Sham UHCDS a-tDCS)
Not yet recruiting
- Fibromyalgia
- Real UHCDS a-tDCS
- +2 more
-
Talavera De La Reina, Toledo, SpainHospital Nuestra Señora del Prado
Feb 13, 2023
Head and Neck Squamous Cell Carcinoma Trial in Spain (Dostarlimab, Niraparib, cisplatin plus radiotherapy)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Dostarlimab
- +2 more
-
Badalona, Cataluña, Spain
- +4 more
Mar 13, 2023
Incorporating Biometric Data for Patients Receiving Concurrent
Not yet recruiting
- Cancer
-
Wilmington, North CarolinaNovant Health Cancer Institute Radiation Oncology
Jul 7, 2023
Pancreatic Carcinoma Trial in Nanjing (Tislelizumab, Gemcitabine, Nab paclitaxel)
Recruiting
- Pancreatic Carcinoma
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Dec 1, 2022
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in China (Cadonilimab, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Nasopharyngeal Cancer
- Cadonilimab
- +3 more
-
Bengbu, Anhui, China
- +12 more
Dec 13, 2022
Cervical Cancer Trial in Shinjuku (LBC, LBC plus HPV DNA testing)
Active, not recruiting
- Cervical Cancer
- LBC
- LBC plus HPV DNA testing
-
Shinjuku, Tokyo, JapanSchool of Medicine, Keio University
Dec 25, 2022
Healthy Volunteers Trial in Medellín (Concurrent exercise, Aerobic exercise)
Recruiting
- Healthy Volunteers
- Concurrent exercise
- Aerobic exercise
-
Medellín, Antioquia, ColombiaUniversidad de Antioquia
May 23, 2023
Uterine Cervical Tumors Trial in Worldwide (biological, drug, radiation)
Recruiting
- Uterine Cervical Neoplasms
- Pembrolizumab
- +4 more
-
Los Angeles, California
- +171 more
Apr 7, 2022
PTSD, Alcohol Use Disorder Trial in New Haven (Brexanolone)
Not yet recruiting
- PTSD
- Alcohol Use Disorder
-
New Haven, ConnecticutYale School of Medicine
Jan 12, 2023
Locally Advanced Head and Neck Squamous Cell Carcinoma Trial in Hamilton, London, Toronto (High-Dose Cisplatin, Low-Dose
Recruiting
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- High-Dose Cisplatin
- +2 more
-
Hamilton, Ontario, Canada
- +2 more
Jun 7, 2022
Glioblastoma Trial in Barcelona, Madrid (Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg)
Not yet recruiting
- Glioblastoma
- Azeliragon 5 mg
- +2 more
-
Barcelona, Spain
- +3 more
Dec 2, 2022
Concurrent Paclitaxel and Radiotherapy After Adjuvant
Not yet recruiting
- Breast Cancer
- Concurrent chemoradiation
- (no location specified)
Oct 16, 2022
Executive Function Trial in Taipei (resistance-aerobic exercise, RA, aerobic-resistance exercise, AR)
Completed
- Executive Function
- resistance-aerobic exercise, RA
- aerobic-resistance exercise, AR
-
Taipei, TaiwanDepartment of Physical Education and Sport Sciences, National Ta
Mar 29, 2022
Limited Stage Small Cell Lung Cancer Trial in Guangzhou (Sugemalimab, Placebo)
Not yet recruiting
- Limited Stage Small Cell Lung Cancer
- Sugemalimab
- Placebo
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 12, 2022
Bladder Cancer Trial in Spain (Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT))
Active, not recruiting
- Bladder Cancer
- Atezolizumab Injection [Tecentriq]
- External Beam Radiation Therapy (EBRT)
-
Manresa, Barcelona, Spain
- +9 more
Oct 25, 2022
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Cervical Cancer Trial in Chongqing (salvage surgery)
Recruiting
- Cervical Cancer
- salvage surgery
-
Chongqing, Chongqing, ChinaChongqing Cancer Hospital
Feb 20, 2023
Early-stage Breast Cancer Trial in Ottawa (Endocrine Therapy and Radiotherapy)
Completed
- Early-stage Breast Cancer
- Endocrine Therapy and Radiotherapy
-
Ottawa, Ontario, CanadaOttawa Hospital Research Institute
Sep 28, 2022
NSCLC (NSCLC) Trial in Worldwide (nivolumab, ipilimumab, durvalumab)
Active, not recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- nivolumab
- +2 more
-
La Jolla, California
- +182 more
Feb 1, 2023